BioPharma Resources

Drug Trial Radar · NCT05039099

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of AP-101 in Participants With Sporadic or SOD1-Associated ALS

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Sep 2, 2021

Primary completion

Aug 13, 2025

Study completion Aug 13, 2025

Sponsor

Lead sponsor
AL-S PharmaIndustry
Sponsor type
Industry
First posted
Sep 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • AP-101Drug

    Participants receive AP-101 by intravenous infusion (IV).

  • PlaceboDrug

    Participants receive placebo by intravenous infusion (IV).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind PeriodTime frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
  2. Number of Participants With Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and ElectrocardiogramsTime frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
  3. Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind PeriodTime frame: From baseline through the 21-day follow-up after Week 24, approximately 27 weeks

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • UC San Diego, ACTRI

    La Jolla, California

  • Department of Neurology, University Hospitals

    Leuven, Belgium

  • ALS clinic at the Kaye Edmonton Clinic, University of Alberta

    Edmonton, Alberta, Canada

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada

  • ALS Research Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Montreal Neurological Institute and Hospital / Dr Genge

    Montreal, Quebec, Canada

  • Charité

    Berlin, Germany

  • Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

    Bonn, Germany

  • Hannover Medical School

    Hanover, Germany

  • Ulm University Hospital

    Ulm, Germany

  • Hanyang University Medical Center

    Seoul, South Korea

  • Studieenheten Akademiskt specialistcentrum, SLSO

    Stockholm, Sweden

  • Norrlands universitetssjukhus/ University Hospital of Northern Sweden (NUS)

    Umeå, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.